With respect to your first question, which pertained to the shortage, and supply, I mentioned earlier the OECD meeting held in Paris at the end of January at the behest of the Canadian government. It was very clear that there was no meaningful cooperation at the international level.
Moreover, it was very obvious that over the past 30 or 40 years, governments, internationally, have not given much thought to developing a financial strategy for manufacturing medical isotopes produced as a result of research. So this therefore is not so evident.
Indeed, it must be understood that these nuclear reactors cannot be handled like a car or a bicycle. They must be maintained, and just to give you an idea of what this involves, the maintenance plan for these reactors is drawn up two or three years ahead of time. When one of these reactors fails, it is practically impossible to reactivate it if it is undergoing maintenance or being used for other pursuits.
In addition, it must be understood that the reactor that produces the most molybdenum and technetium in the world is the Canadian reactor. When you hear that the Petten reactor can increase its production by 50%, the means 50% of its own production, not 50% of the world's production.
For example, the French reactor manufactures only 3% of the world production and the Belgian reactor accounts for 9%. Even if the Belgian reactor increased its production by 50%, this would only constitute 15% of the world's production.
In my opinion, this is not as easy as it may look, and the international governments should have adopted measures long ago. Every year, the reactors are one year older. Their birthdays are not celebrated, but they are one year older.